Enfusion Inc (ENFN)
9.88
+0.19
(+1.96%)
USD |
NYSE |
Nov 14, 16:00
9.88
0.00 (0.00%)
After-Hours: 20:00
Enfusion Research and Development Expense (Quarterly): 6.842M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 6.842M |
| June 30, 2024 | 6.096M |
| March 31, 2024 | 6.551M |
| December 31, 2023 | 6.061M |
| September 30, 2023 | 4.937M |
| June 30, 2023 | 4.464M |
| March 31, 2023 | 4.431M |
| December 31, 2022 | 4.775M |
| September 30, 2022 | 3.864M |
| Date | Value |
|---|---|
| June 30, 2022 | 3.722M |
| March 31, 2022 | 4.802M |
| December 31, 2021 | 146.56M |
| September 30, 2021 | 2.60M |
| June 30, 2021 | 2.041M |
| March 31, 2021 | 2.202M |
| December 31, 2020 | 1.797M |
| September 30, 2020 | 1.642M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.642M
Minimum
Sep 2020
146.56M
Maximum
Dec 2021
12.55M
Average
4.464M
Median
Jun 2023
Research and Development Expense (Quarterly) Benchmarks
| F5 Inc | 123.95M |
| Cognizant Technology Solutions Corp | -- |
| Castellum Inc | -- |
| BM Technologies Inc | -- |
| Marti Technologies Inc | -- |